Difference between revisions of "Part:BBa K3889022"

 
Line 3: Line 3:
 
<partinfo>BBa_K3889022 short</partinfo>
 
<partinfo>BBa_K3889022 short</partinfo>
  
Epitope region of the human protease ovastacin containing active site for ZP2 protein cleavage.Suspected Intrinsically disordered region (IDR) at C-Terminal.
+
Since ovastacin has a eukaryotic origin, this protein undergoes several Post Translational Modifications (PTM) including the addition of disulphide bonds and phosphorylation at serine and tyrosine residues.  
 +
However, our recombinant protein will be produced in a prokaryotic organism which lacks the necessary genes to carry out PTMs. Hence, we used phosphomimetic variant(s) of ovastacin by changing or mutating the serine to aspartic acid and tyrosine to glutamic acid residues at S99, S156, S244 and Y279 (amino acid numbered with reference to pro-ovastacin) respectively. We then used I-TASSER to predict the structure of this phosphomimetic variant.
 +
 
 +
===Protein Sequence===
 +
RLLSAASNKWPMGGDGVVEVPFLLSSKYDEPSRQVILEALAEFERSTCIRFVTYQDQRDFISIIPMYGCFSDVGRSGGMQVVSLAPTCLQKGRGIVL<strong>HELMHVLGFWH</strong>E HTRADRDRYIRVNWNEILPGFEINFIKSRSSNMLTPYDYSSVMHYGRLAFDRRGLPTITPLWAPSVHIGQRWNLSASDITRVLKLEGCS
 +
 
 +
[[File:T--IISER-Tirupati India--Fig3-Phosphomimic Ovastacin.png]]<br>
 +
Fig 3. Phosphomimetic variant of Ovastacin (aspartic acid residues marked with lime and glutamic acid residue marked with cyan)
 +
 
 +
{| class=wikitable
 +
!C-score
 +
! Estimated TM-score
 +
! Estimated RMSD
 +
|-
 +
| 1.84
 +
| 0.97±0.05
 +
| 1.8±1.
 +
|}
 +
 
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here

Revision as of 22:07, 17 October 2021


Human Ovastacin protease phosphomimic_A

Since ovastacin has a eukaryotic origin, this protein undergoes several Post Translational Modifications (PTM) including the addition of disulphide bonds and phosphorylation at serine and tyrosine residues. However, our recombinant protein will be produced in a prokaryotic organism which lacks the necessary genes to carry out PTMs. Hence, we used phosphomimetic variant(s) of ovastacin by changing or mutating the serine to aspartic acid and tyrosine to glutamic acid residues at S99, S156, S244 and Y279 (amino acid numbered with reference to pro-ovastacin) respectively. We then used I-TASSER to predict the structure of this phosphomimetic variant.

Protein Sequence

RLLSAASNKWPMGGDGVVEVPFLLSSKYDEPSRQVILEALAEFERSTCIRFVTYQDQRDFISIIPMYGCFSDVGRSGGMQVVSLAPTCLQKGRGIVLHELMHVLGFWHE HTRADRDRYIRVNWNEILPGFEINFIKSRSSNMLTPYDYSSVMHYGRLAFDRRGLPTITPLWAPSVHIGQRWNLSASDITRVLKLEGCS

T--IISER-Tirupati India--Fig3-Phosphomimic Ovastacin.png
Fig 3. Phosphomimetic variant of Ovastacin (aspartic acid residues marked with lime and glutamic acid residue marked with cyan)

C-score Estimated TM-score Estimated RMSD
1.84 0.97±0.05 1.8±1.5Å


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]